Sodium-glucose co-transporter-2 antagonist (SGLT2i) drugs are used to control hyperinsulinemia in horses but are associated with development of hypertriglyceridemia. Clinical laboratory submissions were examined from 985 horses sampled within 60 days of starting SGLT2i therapy. Signalment data, drug identity and time of year were examined for association with serum triglyceride (TG) concentration post-treatment with the SGLT2i drugs canagliflozin and ertugliflozin. The study also examined associations between TG and other post-treatment markers including insulin, glucose, adrenocorticotropin (ACTH), total adiponectin and gamma-glutamyl transferase (GGT). Variables associated with higher post-treatment TG included Shetland ponies, Dartmoor ponies and canagliflozin (Shetland mean ratio 1.87, 95% CI 1.37-2.56, P<0.001; Dartmoor mean ratio 2.21, 95% CI 1.33-3.67 P=0.002; Canagliflozin mean ratio 1.23, 95% CI 1.04-1.46 P=0.018). Warmbloods had lower post-treatment TG (mean ratio 0.67, 95% CI 0.45-1.00, P=0.048). Horses with moderate TG increases (2.5-5.0 mmol/L) were more likely to be Shetland ponies (OR 2.32, 95% CI 1.21-4.45, P=0.011) and to be older (OR 1.03 95% CI 1.01-1.06, P=0.017) and less likely to be Connemara ponies (OR 0.23, 95% CI 0.06-0.84, P=0.026), Warmbloods (OR 0.12, 95% CI 0.02-1.00, P=0.049) or receiving ertugliflozin (OR 0.57, 95% CI 0.37-0.87, P=0.010). Post-treatment insulin was negatively associated with post-treatment TG (P=0.001). Shetland and Dartmoor ponies were more likely to suffer hypertriglyceridemia when treated with SGLT2i drugs, and Warmbloods appeared less likely. Some effect of older age and use of canagliflozin were also seen leading to recommendations to consider alternative dosing strategies with this drug, especially when used in high-risk breeds.